본문 바로가기
KERD
논문KCI 등재

Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study

신재일|김승업|김범경|Seoyeon Park|Lee Smith|Dong Keon Yon|Sungchul Choi|Seung Won Lee|Han Gyeol Lee|Ho Hyeok Chang|Ai Koyanagi|Louis Jacob|Elena Dragioti|Joaquim Radua
대한간학회 (The korean Association for the Study of the Liver)|2023.04|Clinical and Molecular Hepatology|제29권 제2호|pp. 433-452

2

조회

0

다운로드

7

인용

0

참고문헌

키워드

IncidenceMortalityAetiologyGlobal burdenPrimary liver cancer

초록

Background/Aims: Global distribution of dominant liver cancer aetiologies has significantly changed over the past decades. This study analyzed the updated temporal trends of liver cancer aetiologies and sociodemographic status in 204 countries and territories from 1990 to 2019. Methods: The Global Burden of Disease 2019 report was used for statistical analysis. In addition, we performed stratification analysis to five quintiles using sociodemographic index and 21 geographic regions. Results: The crude numbers of liver cancer disease-adjusted life years (DALYs) and deaths significantly increased during the study period (DALYs; 11,278,630 in 1990 and 12,528,422 in 2019, deaths; 365,215 in 1990 and 484,577 in 2019). However, the Age-standardized DALY and mortality rates decreased. Hepatitis B virus (HBV) remains the leading cause of liver cancer DALYs and mortality, followed by hepatitis C virus (HCV), alcohol consumption, and non-alcoholic steatohepatitis/non-alcoholic fatty liver disease (NASH/NAFLD). Although Age-standardized DALY and mortality rates of liver cancer due to HBV and HCV have decreased, the rates due to alcohol consumption and NASH/NAFLD have increased. In 2019, the population of the East Asia region had the highest Age-standardized DALY and mortality rates, followed by high-income Asia-Pacific and Central Asia populations. Although East Asia and high-income Asia-Pacific regions showed a decrease during the study period, Age-standardized DALY rates increased in Central Asia. High-income North American and Australasian populations also showed a significant increase in Age-standardized DALY. Conclusions: Liver cancer remains an ongoing global threat. The burden of liver cancer associated with alcohol consumption and NASH/NAFLD is markedly increasing and projected to continuously increase.

Abstract

Background/Aims: Global distribution of dominant liver cancer aetiologies has significantly changed over the past decades. This study analyzed the updated temporal trends of liver cancer aetiologies and sociodemographic status in 204 countries and territories from 1990 to 2019. Methods: The Global Burden of Disease 2019 report was used for statistical analysis. In addition, we performed stratification analysis to five quintiles using sociodemographic index and 21 geographic regions. Results: The crude numbers of liver cancer disease-adjusted life years (DALYs) and deaths significantly increased during the study period (DALYs; 11,278,630 in 1990 and 12,528,422 in 2019, deaths; 365,215 in 1990 and 484,577 in 2019). However, the Age-standardized DALY and mortality rates decreased. Hepatitis B virus (HBV) remains the leading cause of liver cancer DALYs and mortality, followed by hepatitis C virus (HCV), alcohol consumption, and non-alcoholic steatohepatitis/non-alcoholic fatty liver disease (NASH/NAFLD). Although Age-standardized DALY and mortality rates of liver cancer due to HBV and HCV have decreased, the rates due to alcohol consumption and NASH/NAFLD have increased. In 2019, the population of the East Asia region had the highest Age-standardized DALY and mortality rates, followed by high-income Asia-Pacific and Central Asia populations. Although East Asia and high-income Asia-Pacific regions showed a decrease during the study period, Age-standardized DALY rates increased in Central Asia. High-income North American and Australasian populations also showed a significant increase in Age-standardized DALY. Conclusions: Liver cancer remains an ongoing global threat. The burden of liver cancer associated with alcohol consumption and NASH/NAFLD is markedly increasing and projected to continuously increase.

참고문헌 (69)

  1. Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
  2. Yu S, "Disease burden of liver cancer attributable to specific etiologies in China from 1990 to 2019 : An age-period-cohort analysis", Sci Prog, 104, pp.368504211018081~ (2021)
  3. McGlynn KA, "The global epidemiology of hepatocellular carcinoma : present and future", Clin Liver Dis, 15, pp.223~243 (2011)
  4. Younossi Z, "Global burden of NAFLD and NASH : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 15, pp.11~20 (2018)
  5. GBD 2019 Diseases and Injuries Collaborators, "Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019 : a systematic analysis for the Global Burden of Disease Study 2019", Lancet, 396, pp.1204~1222 (2020)
  6. GBD 2017 Colorectal Cancer Collaborators, "The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017", Lancet Gastroenterol Hepatol, 4, pp.913~933 (2019)
  7. Lee SW, "PRISMA 2020 statement and guidelines for systematic review and meta-analysis articles, and their underlying mathematics : Life Cycle Committee Recommendations", Life Cycle, 2, pp.e9~ (2022)
  8. GBD 2016 Mortality Collaborators, "Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016 : a systematic analysis for the Global Burden of Disease Study 2016", Lancet, 390, pp.1084~1150 (2017)
  9. Global Burden of Disease Liver Cancer Collaboration, "The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level : results from the global burden of disease study 2015", JAMA Oncol, 3, pp.1683~1691 (2017)
  10. Singal AG, "Epidemiology and surveillance for hepatocellular carcinoma : New trends", J Hepatol, 72, pp.250~261 (2020)
  11. Valery PC, "Projections of primary liver cancer to 2030 in 30 countries worldwide", Hepatology, 67, pp.600~611 (2018)
  12. Liu Z, "Global trend of aetiology-based primary liver cancer incidence from 1990 to 2030 : a modelling study", Int J Epidemiol, 50, pp.128~142 (2021)
  13. Foreman KJ, "Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death : reference and alternative scenarios for 2016-40 for 195countries and territories", Lancet, 392, pp.2052~2090 (2018)
  14. Lin L, "The burden and trends of primary liver cancer caused by specific etiologies from 1990 to 2017 at the global, regional, national, age, and sex level results from the global burden of disease study 2017", Liver Cancer, 9, pp.563~582 (2020)
  15. Li C, "The impact of universal hepatitis B vaccine on the trend of liver cancer from the Global Burden of Disease Study 2017", Liver Int, 41, pp.1762~1774 (2021)
  16. Dhanasekaran R, "Hepatitis C and hepatocellular cancer:to treat or not to treat", Clin Liver Dis(Hoboken), 17, pp.169~173 (2021)
  17. Llovet JM, "Hepatocellular carcinoma", Nat Rev Dis Primers, 7, pp.6~ (2021)
  18. MacLachlan JH, "Hepatitis B virus epidemiology", Cold Spring Harb Perspect Med, 5, pp.a021410~ (2015)
  19. Spearman CW, "Hepatitis B in sub-Saharan Africa:strategies to achieve the 2030 elimination targets", Lancet Gastroenterol Hepatol, 2, pp.900~909 (2017)
  20. Sarin SK, "Liver diseases in the Asia-Pacific region : a Lancet Gastroenterology & Hepatology Commission", Lancet Gastroenterol Hepatol, 5, pp.167~228 (2020)
  21. Choi J, "Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virusendemic population", Hepatology, 66, pp.1454~1463 (2017)
  22. Su TH, "HCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy : Is HCC prevented or delayed?", Hepatology, 67, pp.1634~1635 (2018)
  23. Dargan A, "Persistent risk for hepatocellular carcinoma after more than a decade of successful hepatitis B virus suppression", Minerva Gastroenterol Dietol, 63, pp.74~76 (2017)
  24. Shinn BJ, "Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation : The need for hepatitis B virus cure", World J Hepatol, 11, pp.65~73 (2019)
  25. D’Ambrosio R, "Directacting antivirals : the endgame for hepatitis C?", Curr Opin Virol, 24, pp.31~37 (2017)
  26. Kanwal F, "Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents", Gastroenterology, 153, pp.996~1005 (2017)
  27. Janjua NZ, "The impact of SVR from direct-acting antiviral-and interferonbased treatments for HCV on hepatocellular carcinoma risk", J Viral Hepat, 27, pp.781~793 (2020)
  28. Ioannou GN, "HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma", J Hepatol (2017)[DOI]
  29. Backus LI, "Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease", Hepatology, 69, pp.487~497 (2019)
  30. Carrat F, "Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study", Lancet, 393, pp.1453~1464 (2019)
  31. Axley P, "Hepatitis C virus and hepatocellular carcinoma : a narrative review", J Clin Transl Hepatol, 6, pp.79~84 (2018)
  32. Ryerson AB, "Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer", Cancer, 122, pp.1312~1337 (2016)
  33. Islami F, "Annual Report to the Nation on the Status of Cancer, Part 1 : national cancer statistics", J Natl Cancer Inst, 113, pp.1648~1669 (2021)
  34. Dore GJ, "Epidemiology of hepatitis C virus infection in Australia", J Clin Virol, 26, pp.171~184 (2003)
  35. Barber MJ, "Price of a hepatitis C cure : Cost of production and current prices for direct-acting antivirals in 50 countries", J Virus Erad, 6, pp.100001~ (2020)
  36. Graham CS, "The current status of US and global access to directacting antiviral regimens for hepatitis C virus infection", Clin Liver Dis(Hoboken), 16, pp.16~19 (2020)
  37. "Hepatitis C"[URL]
  38. Lee JS, "Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea", J Gastroenterol Hepatol, 36, pp.2479~2485 (2021)
  39. Hye-Lin Kim, "A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective", Clinical and Molecular Hepatology, 28(1), pp.91~104 (2022), 대한간학회[DOI]
  40. Chung-Feng Huang, "Scaling up the in-hospital hepatitis C virus care cascade in Taiwan", Clinical and Molecular Hepatology, 27(1), pp.136~143 (2021), 대한간학회[DOI]
  41. Omar Alshuwaykh, "Current and future strategies for the treatment of chronic hepatitis C", Clinical and Molecular Hepatology, 27(2), pp.246~256 (2021), 대한간학회[DOI]
  42. Bailey JR, "Approaches, progress, and challenges to hepatitis C vaccine development", Gastroenterology, 156, pp.418~430 (2019)
  43. Cox AL, "Challenges and promise of a hepatitis C virus vaccine", Cold Spring Harb Perspect Med, 10, pp.a036947~ (2020)
  44. Rumgay H, "Global burden of cancer in 2020 attributable to alcohol consumption : a population-based study", Lancet Oncol, 22, pp.1071~1080 (2021)
  45. Grundy A, "Cancer incidence attributable to alcohol consumption in Alberta in 2012", CMAJ Open, 4, pp.E507~E514 (2016)
  46. "Global information system on alcohol and health - Alcohol, total per capita (15+) consumption (in litres of pure alcohol) (SDG Indicator 3.5.2)"[URL]
  47. Paik JM, "Changes in the global burden of chronic liver diseases from 2012 to 2017 : The growing impact of NAFLD", Hepatology, 72, pp.1605~1616 (2020)
  48. Paik JM, "Nonalcoholic fatty liver disease and alcoholic liver disease are major drivers of liver mortality in the United States", Hepatol Commun, 4, pp.890~903 (2020)
  49. Ge X, "Prevalence trends in nonalcoholic fatty liver disease at the global, regional and national levels, 1990-2017 : a population-based observational study", BMJ Open, 10, pp.e036663~ (2020)
  50. Mitra S, "Epidemiology of non-alcoholic and alcoholic fatty liver diseases", Transl Gastroenterol Hepatol, 5, pp.16~ (2020)
  51. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
  52. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
  53. Estes C, "Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease", Hepatology, 67, pp.123~133 (2018)
  54. Estes C, "Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030", J Hepatol, 69, pp.896~904 (2018)
  55. Noureddin M, "Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma", Clin Liver Dis, 19, pp.361~379 (2015)
  56. Naoshi Nishida, "Metabolic disease as a risk of hepatocellular carcinoma", Clinical and Molecular Hepatology, 27(1), pp.87~90 (2021), 대한간학회[DOI]
  57. Huang DQ, "Global epidemiology of NAFLD-related HCC : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 18, pp.223~238 (2021)
  58. Won Sohn, "Obesity and the risk of primary liver cancer: A systematic review and meta-analysis", Clinical and Molecular Hepatology, 27(1), pp.157~174 (2021), 대한간학회[DOI]
  59. Theresa J. Hydes, "Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH", Clinical and Molecular Hepatology, 26(4), pp.383~400 (2020), 대한간학회[DOI]
  60. Lange NF, "Prevention of NAFLD-associated HCC : Role of lifestyle and chemoprevention", J Hepatol, 75, pp.1217~1227 (2021)
  61. Seung Ha Park, "Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017", Clinical and Molecular Hepatology, 26(2), pp.209~215 (2020), 대한간학회[DOI]
  62. Kim SY, "Trends in alcohol consumption for Korean adults from 1998 to 2018 : Korea national health and nutritional examination survey", Nutrients, 13, pp.609~ (2021)
  63. Li CL, "Androgen receptor enhances hepatic telomerase reverse transcriptase gene transcription after hepatitis B virus integration or point mutation in promoter region", Hepatology, 69, pp.498~512 (2019)
  64. Ruggieri A, "Sex-dependent outcome of hepatitis B and C viruses infections : synergy of sex hormones and immune responses?", Front Immunol, 9, pp.2302~ (2018)
  65. Zhao P, "Epigenetic mechanisms involved in HCV-induced hepatocellular carcinoma(HCC)", Front Oncol, 11, pp.677926~ (2021)
  66. Matsushita H, "Alcohol and hepatocellular carcinoma", BMJ Open Gastroenterol, 6, pp.e000260~ (2019)
  67. Li Y, "Recent advances in the molecular mechanism of sex disparity in hepatocellular carcinoma", Oncol Lett, 17, pp.4222~4228 (2019)
  68. Garate-Carrillo A, "Sex related differences in the pathogenesis of organ fibrosis", Transl Res, 222, pp.41~55 (2020)
  69. McGlynn KA, "Menopausal hormone therapy use and risk of primary liver cancer in the clinical practice research datalink", Int J Cancer, 138, pp.2146~2153 (2016)

관련 논문AI추천

Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021Alexandre Louvet, Banthoon Sukphutanan, Eduardo Fuentes-López, Francisco Idalsoaga, Hanna L. Blaney, Jeffrey V. Lazarus, Juan Pablo Arab, Jürgen Rehm, Kanokphong Suparan, Karn Wijarnpreecha, Lorenzo Leggio, Luis Antonio Díaz, Mazen Noureddin, Patrick S. Kamath, Philippe Mathurin, Pojsakorn Danpanichkul, Primrose Tothanarungroj, Rohit Loomba, Siwanart Kongarin, Supapitch Sirimangklanurak, Thanida Auttapracha, Trenton M. White, Yanfang Pang대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호The current trends in the health burden of primary liver cancer across the globeAijaz Ahmed, Donghee Kim, Peter Konyn대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific RegionChing-Lung Lai, Man-Fung Yuen, Ran Xu Zhu, Wai-Kay Seto거트앤리버 소화기연관학회협의회 · Gut and Liver2016 · 제10권 제3호The latest global burden of liver cancer: A past and present threat전대원, Joo Hyun Oh대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United StatesAmit G. Singal, Daniel Q. Huang, Donghee Kim, Juan Pablo Arab, Ju Dong Yang, Karn Wijarnpreecha, Kwanjit Duangsonk, Luis Antonio Díaz, Mark D. Muthiah, Mazen Noureddin, Pimtawan Jatupornpakdee, Pojsakorn Danpanichkul, Primrose Tothanarungroj, Suthat Liangpunsakul, Tanuj Mahendru, Won-Mook Choi, Yanfang Pang대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제3호Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysisAlessandro Vitale, Anjiya Shaikh, Beom Kyung Kim, Cameron Gofton, George Cholankeril, Gianluca Svegliati-Baroni, Guy D. Eslick, Harry Crane, Jacob George, Jian-Hong Zhong, Mark Cheah, Mi Na Kim, Sang Hoon Ahn, Simone I Strasser대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제3호

이 간행물의 다른 논문 (53건)

Congratulatory remarksSi Hyun Baepp. 1-1Special thanksSeung Up Kimpp. 4-4MAFLD: How is it different from NAFLD?Ming-Hua Zheng, Jacob George, Cameron Gofton, Yadhavan Upendranpp. 17-31Global incidence and prevalence of nonalcoholic fatty liver diseaseEunice Tan, Mark D. Muthiah, Cheng Han Ng, Margaret LP Teng, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Daniel Q. Huangpp. 32-42Nonalcoholic fatty liver disease and non-liver comorbiditiesRichie Manikat, Mindie H. Nguyenpp. 86-102
원문 보기